Chaozhao Liang Selected Research

Castration

1/2023	Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.
10/2022	Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
9/2021	N-Myc promotes angiogenesis and therapeutic resistance of prostate cancer by TEM8.
11/2020	N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1.
1/2019	ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
1/2019	Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
6/2012	Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chaozhao Liang Research Topics

Disease

64	Neoplasms (Cancer) 04/2024 - 12/2010
39	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 06/2012
21	Prostatitis 03/2024 - 01/2015
18	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 12/2010
17	Urinary Bladder Neoplasms (Bladder Cancer) 01/2023 - 03/2011
10	Pelvic Pain 03/2024 - 09/2019
9	Neoplasm Metastasis (Metastasis) 04/2024 - 12/2010
9	Inflammation (Inflammations) 03/2024 - 08/2018
8	Carcinoma (Carcinomatosis) 12/2022 - 01/2011
7	Kidney Calculi (Kidney Stone) 01/2022 - 01/2015
7	Carcinogenesis 12/2021 - 12/2010
6	Pain (Aches) 01/2023 - 01/2020
5	Autosomal Dominant Polycystic Kidney (ADPKD) 09/2020 - 01/2017
5	Premature Ejaculation 09/2019 - 02/2014
4	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 04/2023 - 01/2015
4	Ejaculatory Dysfunction 02/2014 - 06/2013
3	Adenocarcinoma 11/2022 - 06/2012
3	Necrosis 01/2021 - 07/2017
2	Bites and Stings (Sting) 01/2024 - 01/2023
2	Kidney Neoplasms (Kidney Cancer) 07/2023 - 01/2020
2	Fibrosis (Cirrhosis) 04/2023 - 05/2021
2	Calculi (Calculus) 01/2023 - 01/2014
2	Disease Progression 01/2023 - 09/2018
2	COVID-19 01/2022 - 06/2021
2	Genomic Instability 12/2021 - 01/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2021 - 12/2018
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 12/2018
2	Acute Kidney Injury (Acute Renal Failure) 08/2020 - 12/2018
2	Cysts 01/2019 - 01/2018
1	Chronic Pain 03/2024

Drug/Important Bio-Agent (IBA)

12	Proteins (Proteins, Gene)FDA Link 12/2021 - 04/2016
10	MicroRNAs (MicroRNA)IBA 03/2021 - 02/2009
9	CytokinesIBA 03/2024 - 01/2016
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 09/2018
7	Androgen Receptors (Androgen Receptor)IBA 10/2022 - 06/2012
7	AndrogensIBA 10/2022 - 06/2016
7	Messenger RNA (mRNA)IBA 03/2022 - 12/2010
6	Long Noncoding RNAIBA 12/2022 - 01/2019
5	AntigensIBA 12/2023 - 11/2016
5	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2015
5	ORALIT (ORS)IBA 12/2019 - 01/2016
4	Therapeutic UsesIBA 01/2022 - 06/2012
4	Sirolimus (Rapamycin)FDA Link 01/2021 - 01/2017
4	N,N'- dipyridoxylethylenediamine- N,N'- diacetic acid (PLED)IBA 02/2014 - 06/2013
3	LipidsIBA 04/2024 - 03/2015
3	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 12/2013
3	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2020
3	enzalutamideIBA 11/2022 - 01/2019
3	Hormones (Hormone)IBA 10/2022 - 08/2018
3	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2021 - 01/2017
3	Calcium OxalateIBA 01/2021 - 01/2019
3	TOR Serine-Threonine KinasesIBA 11/2019 - 06/2015
3	Mechanistic Target of Rapamycin Complex 1IBA 12/2018 - 06/2015
2	ZincIBA 03/2024 - 12/2018
2	Interleukin-6 (Interleukin 6)IBA 03/2024 - 01/2016
2	InflammasomesIBA 03/2024 - 12/2023
2	Dihydrotestosterone (Androstanolone)IBA 01/2024 - 06/2017
2	InterferonsIBA 01/2024 - 01/2023
2	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2023 - 08/2020
2	Freund's AdjuvantIBA 12/2023 - 01/2021
2	HymecromoneIBA 01/2022 - 10/2021
2	ChemokinesIBA 01/2022 - 01/2016
2	Hyaluronic Acid (Hyaluronan)IBA 01/2022 - 10/2021
2	Phosphotransferases (Kinase)IBA 12/2021 - 12/2018
2	Circular RNAIBA 07/2021 - 09/2019
2	EmetineIBA 06/2021 - 01/2020
2	Antiviral Agents (Antivirals)IBA 06/2021 - 01/2020
2	Indicators and Reagents (Reagents)IBA 01/2021 - 01/2020
2	Arsenic Trioxide (Trisenox)FDA Link 01/2021 - 02/2017
2	p38 Mitogen-Activated Protein KinasesIBA 01/2021 - 07/2017
2	Sirtuin 3IBA 05/2019 - 01/2019
2	Everolimus FDA Link 02/2017 - 06/2012
2	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 10/2016 - 06/2016
2	Interleukin-8 (Interleukin 8)IBA 01/2016 - 06/2012
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2024
1	ST 679IBA 04/2024
1	InterleukinsIBA 03/2024
1	Butyric Acid (Butanoic Acid)IBA 03/2024
1	EnzymesIBA 03/2024
1	ImmunosorbentsIBA 03/2024
1	AntioxidantsIBA 03/2024
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2024
1	MelatoninIBA 01/2024

Therapy/Procedure

31	Therapeutics 01/2024 - 06/2012
9	Immunotherapy 01/2023 - 01/2020
7	Castration 01/2023 - 06/2012
6	Drug Therapy (Chemotherapy) 12/2022 - 02/2019
5	Nephrectomy 12/2022 - 01/2015
4	Extracorporeal Shockwave Therapy 04/2023 - 04/2021
3	Transurethral Resection of Prostate (TURP) 12/2023 - 01/2015
2	Operative Time 03/2023 - 06/2019
2	Aftercare (After-Treatment) 01/2023 - 12/2022
2	Punctures 01/2023 - 01/2020
2	Lasers (Laser) 01/2023 - 01/2014
2	Percutaneous Nephrolithotomy 01/2023 - 09/2020
2	Cystectomy 01/2021 - 01/2018
2	Radiotherapy 01/2020 - 01/2020
2	Ureteroscopes 01/2015 - 01/2014
2	Solid-State Lasers 01/2015 - 01/2014
2	Stents 01/2014 - 01/2014